Medicina (Jun 2023)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives

  • Maria Chiara Lo Greco,
  • Giulia Marletta,
  • Giorgia Marano,
  • Alessandro Fazio,
  • Emanuele Buffettino,
  • Arianna Iudica,
  • Rocco Luca Emanuele Liardo,
  • Roberto Milazzotto,
  • Pietro Valerio Foti,
  • Stefano Palmucci,
  • Antonio Basile,
  • Francesco Marletta,
  • Francesco Cuccia,
  • Giuseppe Ferrera,
  • Silvana Parisi,
  • Antonio Pontoriero,
  • Stefano Pergolizzi,
  • Corrado Spatola

DOI
https://doi.org/10.3390/medicina59061144
Journal volume & issue
Vol. 59, no. 6
p. 1144

Abstract

Read online

At the time of diagnosis, the vast majority of prostate carcinoma patients have a clinically localized form of the disease, with most of them presenting with low- or intermediate-risk prostate cancer. In this setting, various curative-intent alternatives are available, including surgery, external beam radiotherapy and brachytherapy. Randomized clinical trials have demonstrated that moderate hypofractionated radiotherapy can be considered as a valid alternative strategy for localized prostate cancer. High-dose-rate brachytherapy can be administered according to different schedules. Proton beam radiotherapy represents a promising strategy, but further studies are needed to make it more affordable and accessible. At the moment, new technologies such as MRI-guided radiotherapy remain in early stages, but their potential abilities are very promising.

Keywords